BLTE
Belite Bio, Inc NASDAQ$154.85
Mkt Cap $5.2B
52w Low $56.10
68.6% of range
52w High $200.00
50d MA $168.47
200d MA $124.21
P/E (TTM)
-67.0x
EV/EBITDA
-59.5x
P/B
6.7x
Debt/Equity
0.0x
ROE
-10.1%
P/FCF
-144.3x
RSI (14)
—
ATR (14)
—
Beta
-1.22
50d MA
$168.47
200d MA
$124.21
Avg Volume
174.0K
About
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | AMC | -0.56 | -0.38 | +32.1% | 177.58 | +0.0% | -5.5% | +0.1% | -2.8% | -2.4% | +0.9% | -5.8% | — |
| Nov 10, 2025 | AMC | -0.53 | -0.65 | -22.6% | 117.34 | -2.0% | -9.9% | -5.6% | -4.2% | -0.5% | -0.4% | +25.3% | — |
| Aug 11, 2025 | AMC | -0.47 | -0.50 | -6.4% | 69.50 | +0.0% | +4.6% | +3.0% | -0.7% | -4.1% | -6.5% | -4.6% | — |
| May 13, 2025 | AMC | -0.36 | -0.45 | -25.0% | 60.89 | +0.0% | +1.2% | +10.1% | +5.8% | +6.7% | +6.4% | +2.1% | — |
| Mar 17, 2025 | AMC | -0.30 | -0.32 | -6.7% | 67.81 | +0.3% | +0.8% | -0.2% | -0.1% | -0.8% | -1.3% | -15.5% | — |
| Nov 12, 2024 | AMC | -0.30 | -0.28 | +6.7% | 81.15 | +0.1% | +1.3% | +3.1% | +2.0% | +2.0% | +1.5% | -21.9% | — |
| Aug 9, 2024 | AMC | -0.28 | -0.31 | -10.7% | 49.48 | -4.3% | -1.9% | +1.8% | +0.8% | +0.8% | +0.9% | -1.2% | — |
| May 13, 2024 | AMC | -0.34 | -0.27 | +20.6% | 41.69 | -0.8% | +0.7% | +1.8% | +1.7% | +7.9% | +8.3% | +19.9% | — |
| Mar 11, 2024 | AMC | -0.36 | -0.25 | +30.6% | 44.60 | +1.1% | -12.5% | -14.8% | -15.2% | -13.7% | -8.1% | -10.8% | — |
| Nov 13, 2023 | AMC | -0.31 | -0.40 | -29.0% | 39.30 | -2.0% | -3.6% | -5.8% | -5.4% | -5.3% | -2.7% | +12.5% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $165.23 | $168.90 | +2.2% | +1.3% | -0.5% | -2.4% | -1.3% | -3.9% |
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $172.76 | $176.18 | +2.0% | +0.2% | -0.5% | -2.3% | -8.5% | -4.2% |
| Mar 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $177.58 | $177.60 | +0.0% | -5.5% | +0.1% | -2.8% | -2.4% | +0.9% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $177.58 | $177.60 | +0.0% | -5.5% | +0.1% | -2.8% | -2.4% | +0.9% |
| Mar 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $177.58 | $177.60 | +0.0% | -5.5% | +0.1% | -2.8% | -2.4% | +0.9% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $167.34 | $167.09 | -0.1% | -1.0% | +1.0% | +1.0% | +3.6% | +11.9% |
| Dec 2 | Mizuho | Upgrade | Neutral → Outperform | — | $154.02 | $160.43 | +4.2% | -2.1% | -1.4% | -1.8% | -2.6% | -2.7% |
| Dec 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $137.44 | $153.50 | +11.7% | +12.1% | +9.7% | +10.4% | +10.1% | +9.1% |
| Oct 31 | Benchmark | Maintains | Buy → Buy | — | $98.10 | $98.85 | +0.8% | +8.0% | +14.6% | +13.2% | +14.6% | +13.9% |
| Sep 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.48 | $69.60 | +0.2% | -3.9% | -3.7% | +5.1% | +5.4% | +1.0% |
Data updated apr 26, 2026 9:54am
· Source: massive.com